Feeds › Planned insider sales
Planned insider sales
Notices (SEC Form 144) that executives and other insiders file before selling shares, and whether a sale was reported afterwards.
About this data
- What it is
- Before an executive, director or large owner sells restricted or control shares, they file a short notice with the SEC, called Form 144, saying how many shares they plan to sell, through which broker and roughly when. This feed lists those notices, and for each one shows whether a sale was reported afterwards on a Form 4 and how many days later.
- Who files it
- The person selling, or their broker, on the day the sale is placed. Electronic notices start in April 2023.
- How current
- We collect new notices throughout the day on SEC business days.
- Terms
- Form 144The notice an insider or other affiliate of a company files with the SEC before selling restricted or control shares, so the shares can be sold under Rule 144. The notice says how many shares, through which broker, and roughly when.10b5-1 planA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan.
- Worth knowing
- A notice is a plan, not a sale: the person may sell fewer shares, later, or not at all. The value is the one the filer typed, at a price they chose, not what the shares sell for. Many sales are routine, made to diversify or pay taxes, or under a 10b5-1 plan set up months earlier. A blank in the last column does not mean no sale: the person may not have to file a Form 4 (an ordinary affiliate does not), the sale may be recent, or the Form 4 may name a different spelling of the person. We match by the filer's number first and by name second. Information, not investment advice.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Form 144 notices per day, last 30 days
All notices Notices that give a 10b5-1 plan
By the day each notice was filed. A notice is a plan to sell, not a sale.
Latest notices of planned insider sales
Showing: ticker JANX
| Filed | Insider | Company | Shares to sellA notice is a plan, not a sale. The person may sell fewer shares, sell later, or not sell at all, and the number of shares is what they expect to sell on the day they file. | ValueThe aggregate market value the filer typed on the notice: the shares times a price the filer chose. It is not what the shares will sell for. | PlanA Rule 10b5-1 trading plan lets an insider set up future sales in advance, on a schedule or at set prices, at a time when they do not hold inside information. A notice that gives a plan adoption date says the sale is made under such a plan. | Expected sale | Sale reportedInsiders who are officers, directors or hold more than 10% report their sales on a Form 4, within two business days. We look for the first Form 4 with an open-market sale by the same person in the same company within 90 days of the notice, and show how many days after the notice it was filed. A blank means we found none: the person may not have sold, may not have to file a Form 4, or the Form 4 may be one we do not have. | Notice |
|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Noel Doyle Janeen Officer | JANX Janux Therapeutics, Inc. | 4,059 | $56.9K | — | Jun 2, 2026 | Form 4 ↗ 2 days later · 4,059 shares | Form 144 ↗ |
| Apr 13, 2026 | Andy Meyer Former Affiliate | JANX Janux Therapeutics, Inc. | 1,877 | $28.2K | — | Apr 13, 2026 | — | Form 144 ↗ |
| Apr 2, 2026 | Zachariah A McIver Former Officer | JANX Janux Therapeutics, Inc. | 74,802 | $1.1M | — | Apr 2, 2026 | — | Form 144 ↗ |
| Jan 26, 2026 | Andy Meyer Former Affiliate | JANX Janux Therapeutics, Inc. | 178,767 | $2.6M | — | Jan 26, 2026 | — | Form 144 ↗ |
| Jan 23, 2026 | Andy Meyer Former Affiliate | JANX Janux Therapeutics, Inc. | 118,122 | $1.7M | — | Jan 23, 2026 | — | Form 144 ↗ |
| Dec 15, 2025 | Byron C Robinson Officer | JANX Janux Therapeutics, Inc. | 16,666 | $258.4K | — | Dec 15, 2025 | — | Form 144 ↗ |
| Dec 8, 2025 | Byron C Robinson Officer | JANX Janux Therapeutics, Inc. | 50,000 | $826.0K | — | Dec 8, 2025 | — | Form 144 ↗ |
| Dec 2, 2025 | Byron C Robinson Officer | JANX Janux Therapeutics, Inc. | 63,125 | $1.0M | — | Dec 2, 2025 | — | Form 144 ↗ |
| Dec 1, 2025 | Andrew Meyer Officer | JANX Janux Therapeutics, Inc. | 3,333 | $113.6K | 10b5-1 | Dec 1, 2025 | Form 4 ↗ 2 days later · 3,333 shares | Form 144 ↗ |
| Nov 14, 2025 | Andrew Meyer Officer | JANX Janux Therapeutics, Inc. | 3,333 | $91.5K | 10b5-1 | Nov 14, 2025 | Form 4 ↗ same day · 3,333 shares | Form 144 ↗ |
| Oct 28, 2025 | Andrew Meyer Officer | JANX Janux Therapeutics, Inc. | 16,665 | $455.8K | 10b5-1 | Oct 28, 2025 | Form 4 ↗ 2 days later · 16,665 shares | Form 144 ↗ |
| May 1, 2025 | Andrew Meyer Officer | JANX Janux Therapeutics, Inc. | 3,333 | $110.7K | 10b5-1 | May 1, 2025 | Form 4 ↗ 1 day later · 3,333 shares | Form 144 ↗ |
| Apr 21, 2025 | Andrew Meyer Officer | JANX Janux Therapeutics, Inc. | 3,334 | $99.0K | 10b5-1 | Apr 21, 2025 | Form 4 ↗ 2 days later · 3,334 shares | Form 144 ↗ |
| Mar 3, 2025 | Andrew Meyer Officer | JANX Janux Therapeutics, Inc. | 3,334 | $109.7K | 10b5-1 | Mar 3, 2025 | Form 4 ↗ 2 days later · 3,334 shares | Form 144 ↗ |
| Feb 3, 2025 | Andrew Meyer Officer | JANX Janux Therapeutics, Inc. | 3,334 | $145.0K | 10b5-1 | Feb 3, 2025 | Form 4 ↗ 2 days later · 3,334 shares | Form 144 ↗ |
| Jan 7, 2025 | David Alan Campbell Officer | JANX Janux Therapeutics, Inc. | 5,000 | $300.0K | 10b5-1 | Jan 7, 2025 | Form 4 ↗ 1 day later · 5,000 shares | Form 144 ↗ |
| Jan 2, 2025 | Andrew Meyer Officer | JANX Janux Therapeutics, Inc. | 13,334 | $713.9K | 10b5-1 | Jan 2, 2025 | Form 4 ↗ 1 day later · 13,334 shares | Form 144 ↗ |
| Dec 26, 2024 | David Alan Campbell Officer | JANX Janux Therapeutics, Inc. | 25,000 | $1.4M | 10b5-1 | Dec 26, 2024 | Form 4 ↗ 13 days later · 5,000 shares | Form 144 ↗ |
| Nov 1, 2024 | Reardon Tighe FORMER OFFICER | JANX Janux Therapeutics, Inc. | 5,202 | $278.0K | — | Nov 1, 2024 | — | Form 144 ↗ |
| Nov 1, 2024 | Jay Lichter FORMER DIRECTOR | JANX Janux Therapeutics, Inc. | 1,139 | $60.7K | — | Nov 1, 2024 | — | Form 144 ↗ |
| Nov 1, 2024 | Avalon Ventures XI, L.P. 10% Stockholder | JANX Janux Therapeutics, Inc. | 56,440 | $3.0M | — | Nov 1, 2024 | — | Form 144 ↗ |
| Nov 1, 2024 | Avalon BioVentures SPV I, L.P. 10% Stockholder | JANX Janux Therapeutics, Inc. | 57,627 | $3.1M | — | Nov 1, 2024 | — | Form 144 ↗ |
| Nov 1, 2024 | Avalon BioVentures I, LP 10% Stockholder | JANX Janux Therapeutics, Inc. | 10,934 | $586.7K | — | Nov 1, 2024 | — | Form 144 ↗ |
| Nov 1, 2024 | Reardon Tighe Former officer | JANX Janux Therapeutics, Inc. | 2,999 | $158.9K | — | Nov 1, 2024 | — | Form 144 ↗ |
| Oct 28, 2024 | Reardon Tighe FORMER OFFICER | JANX Janux Therapeutics, Inc. | 15,122 | $807.7K | — | Oct 28, 2024 | — | Form 144 ↗ |
| Oct 28, 2024 | Jay Lichter FORMER DIRECTOR | JANX Janux Therapeutics, Inc. | 3,419 | $183.0K | — | Oct 28, 2024 | — | Form 144 ↗ |
| Oct 28, 2024 | Reardon Tighe Former officer | JANX Janux Therapeutics, Inc. | 9,061 | $483.5K | — | Oct 28, 2024 | — | Form 144 ↗ |
| Oct 25, 2024 amended | Reardon Tighe Former Officer | JANX Janux Therapeutics, Inc. | 21,760 | $1.1M | — | Oct 24, 2024 | — | Form 144/A ↗ |
| Oct 25, 2024 | Avalon Ventures XI, L.P. 10% Stockholder | JANX Janux Therapeutics, Inc. | 169,320 | $9.0M | — | Oct 25, 2024 | — | Form 144 ↗ |
| Oct 25, 2024 | Avalon BioVentures I, LP 10% Stockholder | JANX Janux Therapeutics, Inc. | 32,800 | $1.7M | — | Oct 25, 2024 | — | Form 144 ↗ |
| Oct 25, 2024 | Avalon BioVentures SPV I, L.P. 10% Stockholder | JANX Janux Therapeutics, Inc. | 172,880 | $9.2M | — | Oct 25, 2024 | — | Form 144 ↗ |
| Oct 24, 2024 | Jay Lichter FORMER DIRECTOR | JANX Janux Therapeutics, Inc. | 4,921 | $262.7K | — | Oct 24, 2024 | — | Form 144 ↗ |
| Oct 24, 2024 | Reardon Tighe FORMER OFFICER | JANX Janux Therapeutics, Inc. | 217,690 | $1.1M | — | Oct 24, 2024 | — | Form 144 ↗ |
| Oct 23, 2024 | Avalon BioVentures SPV I, L.P. 10% Stockholder | JANX Janux Therapeutics, Inc. | 248,797 | $12.7M | — | Oct 23, 2024 | — | Form 144 ↗ |
| Oct 23, 2024 | Avalon BioVentures I, LP 10% Stockholder | JANX Janux Therapeutics, Inc. | 47,203 | $2.4M | — | Oct 23, 2024 | — | Form 144 ↗ |
| Oct 23, 2024 | Avalon Ventures XI, L.P. 10% Stockholder | JANX Janux Therapeutics, Inc. | 243,672 | $12.5M | — | Oct 23, 2024 | — | Form 144 ↗ |
| Oct 23, 2024 | Reardon Tighe Former officer | JANX Janux Therapeutics, Inc. | 13,039 | $665.1K | — | Oct 23, 2024 | — | Form 144 ↗ |
| Oct 21, 2024 | Reardon Tighe FORMER OFFICER | JANX Janux Therapeutics, Inc. | 10,769 | $532.3K | — | Oct 21, 2024 | — | Form 144 ↗ |
| Oct 21, 2024 | Jay Lichter FORMER DIRECTOR | JANX Janux Therapeutics, Inc. | 2,434 | $120.5K | — | Oct 21, 2024 | Form 4 ↗ -3 days later · 1.46M shares | Form 144 ↗ |
| Oct 21, 2024 | Reardon Tighe Former officer | JANX Janux Therapeutics, Inc. | 6,324 | $317.5K | — | Oct 21, 2024 | — | Form 144 ↗ |
| Oct 18, 2024 | Avalon Ventures XI, L.P. 10% Stockholder | JANX Janux Therapeutics, Inc. | 118,194 | $6.0M | — | Oct 18, 2024 | Form 4 ↗ same day · 1.67M shares | Form 144 ↗ |
| Oct 18, 2024 | Avalon BioVentures I, LP 10% Stockholder | JANX Janux Therapeutics, Inc. | 22,895 | $1.2M | — | Oct 18, 2024 | Form 4 ↗ same day · 1.67M shares | Form 144 ↗ |
| Oct 18, 2024 | Avalon BioVentures SPV I, L.P. 10% Stockholder | JANX Janux Therapeutics, Inc. | 120,680 | $6.1M | — | Oct 18, 2024 | Form 4 ↗ same day · 1.67M shares | Form 144 ↗ |
| Oct 17, 2024 | Reardon Tighe FORMER OFFICER | JANX Janux Therapeutics, Inc. | 8,158 | $408.0K | — | Oct 17, 2024 | — | Form 144 ↗ |
| Oct 17, 2024 | Jay Lichter FORMER DIRECTOR | JANX Janux Therapeutics, Inc. | 1,842 | $92.2K | — | Oct 17, 2024 | Form 4 ↗ 1 day later · 1.67M shares | Form 144 ↗ |
| Oct 17, 2024 | Reardon Tighe Former officer | JANX Janux Therapeutics, Inc. | 4,784 | $237.6K | — | Oct 17, 2024 | — | Form 144 ↗ |
| Oct 16, 2024 | Reardon Tighe FORMER OFFICER | JANX Janux Therapeutics, Inc. | 48,462 | $2.5M | — | Oct 16, 2024 | — | Form 144 ↗ |
| Oct 16, 2024 | Jay Lichter FORMER DIRECTOR | JANX Janux Therapeutics, Inc. | 10,957 | $556.6K | — | Oct 16, 2024 | Form 4 ↗ 2 days later · 1.67M shares | Form 144 ↗ |
| Oct 16, 2024 | Avalon BioVentures I, LP 10% Stockholder | JANX Janux Therapeutics, Inc. | 17,367 | $867.6K | — | Oct 16, 2024 | Form 4 ↗ 2 days later · 1.67M shares | Form 144 ↗ |
| Oct 16, 2024 | Avalon BioVentures SPV I, L.P. 10% Stockholder | JANX Janux Therapeutics, Inc. | 91,539 | $4.6M | — | Oct 16, 2024 | Form 4 ↗ 2 days later · 1.67M shares | Form 144 ↗ |
The newest 50 items, most recent first. Every row links to the notice on the SEC's site, and to the Form 4 when we found one. Updated Nov 15, 2026, 10:56 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances